Overview

Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if Tarceva ® (erlotinib) when taken before and after radiation and/or surgery can help to control aggressive cutaneous squamous cell carcinoma. The safety of the drug will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
OSI Pharmaceuticals
Treatments:
Erlotinib Hydrochloride